Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: A phase II study in pretreated patients with metastatic colorectal cancer

Pasquale Comella, Bruno Massidda, Sergio Palmeri, Carlo Putzu, Vincenzo De Rosa, Francesco Izzo, Francesco Fiore, Rossana Casaretti, Claudia Sandomenico

Research output: Contribution to journalArticle

Abstract

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU). We carried out this phase II study to assess the activity and toxicity of a biweekly regimen including OXA plus IRI on day 1, and levo-folinic acid (LFA) plus 5FU on day 2 (OXIRIFAFU) in pretreated patients with metastatic colorectal cancer. Forty-one patients, all previously treated with adjuvant and/or palliative 5FU-based chemotherapy (16 of them already exposed to IRI, OXA or both), were enrolled into this trial. On the basis of sensitivity to previous treatment, 19 patients were considered as chemo-resistant and 14 patients as chemo-refractory. OXA 110 mg/m (over 2 h) and IRI 175 mg/m (over 1 h) were delivered on day 1, followed by LFA 250 mg/m (2-h infusion) plus 5FU 800 mg/m as intravenous bolus on day 2. Cycles were repeated every 2 weeks. A total of 348 cycles were delivered, with a median of nine cycles per patient (range, 1-12 cycles per patient). Five complete and 13 partial responses were reported on 40 assessable patients, giving a response rate of 45% [95% confidence interval (CI), 29-62%]; eight of 19 (42%) resistant patients and five of 14 (36%) refractory patients achieved a major response, which was also obtained in four of eight (50%) patients pretreated with IRI and in three of eight (38%) patients pretreated with OXA. Grade 3 or higher neutropenia occurred in 68% of patients, but febrile neutropenia or infections affected only seven (17%) patients. No episodes of grade 3 or higher thrombocytopenia or anemia were recorded. Occurrence of severe non-hematologic toxicities by patients were: diarrhea, 34%; vomiting, 17%; peripheral cumulative neuropathy, 15%; stomatitis, 10%; acute cholinergic syndrome, 7%. Actually delivered dose intensities of all three drugs resulted in about two-thirds of the planned ones. After a follow-up of 39 months, median progression-free survival was 7.5 months. Median overall survival was 14.4 (95% CI, 10.4-18.4) months from the start of OXIRIFAFU and 25.3 (95% CI, 18.1-32.5) months from the diagnosis of metastatic disease. This OXIRIFAFU triplet regimen was highly effective in resistant/refractory colorectal cancer patients. A slight dose reduction of all cytotoxic drugs could be advisable in order to improve the tolerability of this regimen without jeopardizing its activity.

Original languageEnglish
Pages (from-to)985-992
Number of pages8
JournalAnti-Cancer Drugs
Volume17
Issue number8
DOIs
Publication statusPublished - Sep 2006

Keywords

  • 5-fluorouracil
  • Biweekly regimen
  • Colorectal carcinoma
  • Irinotecan
  • Oxaliplatin
  • Triplet regimen

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: A phase II study in pretreated patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this